Tidal Investments’s UroGen Pharma URGN Stock Holding History

Tidal Investments’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75M	Sell	101,837 -1,112	-1%	-$30.1K	0.01%	1065
2026 Q1	$1.85M	Buy	102,949 +75,977	+282%	+$1.52M	﹤0.01%	1173
2025 Q4	$632K	Buy	+26,972	New	+$585K	﹤0.01%	1517
2025 Q2	–	Sell	-29,679	Closed	-$328K	–	2072
2025 Q1	$328K	Sell	29,679 -847	-3%	-$9.03K	﹤0.01%	1517
2024 Q4	$325K	Sell	30,526 -7,069	-19%	-$84.6K	﹤0.01%	1562
2024 Q3	$477K	Buy	37,595 +6,030	+19%	+$89.5K	0.01%	1403
2024 Q2	$530K	Buy	31,565 +3,245	+11%	+$46.2K	0.01%	1280
2024 Q1	$425K	Buy	+28,320	New	+$463K	0.01%	1254

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Tidal Investments's URGN Position: Q2 2026 in Review

Tidal Investments reduced its UroGen Pharma (URGN) stake by 1.1% in Q2 2026, selling an estimated $30.1K and leaving 101,837 shares worth $3.75M. The position accounts for 0.01% of the portfolio, ranked #1065.

Tidal Investments first reported a position in URGN in Q1 2024 and has held it in 8 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Tidal Investments held 101,837 shares of UroGen Pharma worth $3.75M as of Q2 2026.
Tidal Investments sold 1,112 UroGen Pharma shares in Q2 2026, an estimated $30.1K.
UroGen Pharma made up 0.01% of Tidal Investments's portfolio in Q2 2026, its #1065 holding.
Tidal Investments first reported a position in UroGen Pharma in Q1 2024 and has held it in 8 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.